Luciana Lastrucci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luciana Lastrucci has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Aroldo Marconi
Breast Oncological and Reconstructive Surgery, S.Luca Hospital- V. G. Lippi Francesconi, Lucca, Italy
1 shared publication - Carlotta Becherini
Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
1 shared publication - Carmelo Bengala
Oncology Department, Unit of Medical Oncology, Misericordia Hospital, Grosseto, Italy
1 shared publication - Catia Angiolini
SOD Oncologia della Mammella, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
1 shared publication - Donato Casella
Oncologic Breast Surgery Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy
1 shared publication - Gianni Amunni
Azienda Ospedaliero Universitaria Careggi, Florence, Italy
1 shared publication
Latest Publications
- 29 April 2024
- Published by Springer Nature in La radiologia medica
- Vol. 129 (6) , 945-954
Management of the axilla in breast cancer patients: critical review, regional modified Delphi consensus and implementation in the Tuscan breast network
Purpose Data from recently trials have provided practice-changing recommendations in management of the axilla in early breast cancer (eBC). However, further controversies have been raised, resulting in heterogeneous diffusion of these recommendations. Our purpose was to obtain a better homogeneity. Material and methods In 2021, the Tuscan Breast Network (TBN) established a consensus with the aim to update recommendations in this area. We performed a literature review on axillary management in eBC patients which led to an expert Delphi consensus aiming to explore the gray areas, build consensus and propose evidence-based suggestions for an appropriate management. Thereafter, we investigate their implementation in clinical practice. Results (1) DCIS patients should have SLN biopsy only in case of mastectomy or in conservative surgery if tumor is in a location that would preclude future nodal sampling or in case of a mass; (2) ALND may be omitted for 1–2 positive SLN patients undergoing BCS in T1-2 tumors with 1–2 SLN positive, eligible for whole-breast irradiation and adjuvant systemic therapies; (3) consider the option of RNI in patients with 1–3 positive lymph nodes and one or more high-risk characteristics; (4) the population identified in 2) should NOT undergo lymph node irradiation as an alternative to axillary surgery and (5) patients with clinically (pre-operatively) positive axilla, or undergoing primary systemic therapy, or outside the criteria reported in 2) must receive additional ALND and/or RT as per local policy. Conclusion This consensus provided a practical tool to stimulate local and national breast surgical and radiotherapy protocols.
- 29 April 2024
- Published by Springer Nature in La radiologia medica
- Vol. 129 (6) , 945-954
Management of the axilla in breast cancer patients: critical review, regional modified Delphi consensus and implementation in the Tuscan breast network
Purpose Data from recently trials have provided practice-changing recommendations in management of the axilla in early breast cancer (eBC). However, further controversies have been raised, resulting in heterogeneous diffusion of these recommendations. Our purpose was to obtain a better homogeneity. Material and methods In 2021, the Tuscan Breast Network (TBN) established a consensus with the aim to update recommendations in this area. We performed a literature review on axillary management in eBC patients which led to an expert Delphi consensus aiming to explore the gray areas, build consensus and propose evidence-based suggestions for an appropriate management. Thereafter, we investigate their implementation in clinical practice. Results (1) DCIS patients should have SLN biopsy only in case of mastectomy or in conservative surgery if tumor is in a location that would preclude future nodal sampling or in case of a mass; (2) ALND may be omitted for 1–2 positive SLN patients undergoing BCS in T1-2 tumors with 1–2 SLN positive, eligible for whole-breast irradiation and adjuvant systemic therapies; (3) consider the option of RNI in patients with 1–3 positive lymph nodes and one or more high-risk characteristics; (4) the population identified in 2) should NOT undergo lymph node irradiation as an alternative to axillary surgery and (5) patients with clinically (pre-operatively) positive axilla, or undergoing primary systemic therapy, or outside the criteria reported in 2) must receive additional ALND and/or RT as per local policy. Conclusion This consensus provided a practical tool to stimulate local and national breast surgical and radiotherapy protocols.